Xingbao Tao

Xingbao Tao

Auto-generated profile, based on publicly available information

Xingbao Tao

School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
XTXingbao Tao
Xingbao Tao
YLYanqiu Lu
Yanqiu Lu
YZYihong Zhou
Yihong Zhou
LZLvlang Zhang
Lvlang Zhang
YCYaokai Chen
Yaokai Chen
Tenofovir disoproxil fumarate (TDF) can cause renal and bone toxicity, which is associated with high plasma tenofovir concentrations in antiretroviral treatment of HIV-1 infected patients. Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. We aimed to assess the non-inferiority of a TAF-containing combination regimen versus a TDF-containing fixed-dose single-tablet regimen in the antiretroviral-treatment-naive, HIV-1-infected patients. We searched PubMed, Embase, Web of Science, and the Cochrane Trial Registry, from January 2001 to July 2019, using relevant keywords. Available data were extracted from eligible randomized trials (RCTs) and pooled as risk ratios (RRs) or standardized mean differences (SMDs) in a meta-analysis model using Stata/SE. We included seven eligible randomized controlled trials (RCTs) with a total of 6269 participants. Patients who were antiretroviral-naive adults with HIV-1 on both the TAF-containing regimens and the TDF-containing regimens had similar virologic suppression effects (RR, 1.02; 95% CI, 1.00-1.04; p > 0.05) at week 24 (93.99% vs. 94.20%), week 48 (90.71% vs. 89.54%), and week 96 (86.16% vs. 84.80%). Both groups had no significant improvements in CD4 cell count for the naive patients during 48 weeks of therapy (SMD, 0.09; 95% CI, 0.01 to 0.16; p < 0.05). Both treatments were safe and well-tolerated, and most adverse events were similar as mild to moderate in severity. Moreover, compared with the TDF-containing regimens, the TAF-containing regimens in patients had significantly smaller reductions in both hip (RR, 0.33; 95CI, 0.29-0.39; p < 0.05) and spine (RR, 0.58; 95CI, 0.51-0.65; p < 0.05). Additionally, the TAF-containing regimens in patients had significantly fewer increases for renal events than those of the TDF-containing regimens through 48 weeks (0.31; 95% CI, 0.18-0.55; p < 0.05). Our meta-analysis indicated that efficacy, safety, and tolerability of TAF-containing regimens were non-inferior in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection. Furthermore, compared with those receiving the TDF-containing regimens, patients on the TAF-containing regimens had significant advantages in renal function, bone parameters, and lipid profile for the naive patients.

7 June 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XTXingbao Tao
Xingbao Tao
HLHongbo Liu
Hongbo Liu
JXJie Xia
Jie Xia
PZPing Zeng
Ping Zeng
HWHepeng Wang
Hepeng Wang
HWHao Wu
Hao Wu

1 October 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
XTXingbao Tao
Xingbao Tao
YLYanqiu Lu
Yanqiu Lu
YZYihong Zhou
Yihong Zhou
YHYinqiu Huang
Yinqiu Huang
YCYaokai Chen
Yaokai Chen
To investigate whether TDF-containing regimens significantly benefited efficacy, safety, and tolerability in TAF-containing regimens in virologically suppressed HIV-infected patients. PubMed, Embase, Web of Science, and the Cochrane Trial Registry were systematically searched for eligible studies. We extracted and evaluated the pooled data from available randomized controlled trials (RCTs). Eight eligible RCTs were included. In the intention-to-treat (ITT) analysis, patients who switched to TAF-containing regimens had significantly better viral suppression than those continuing TDF-containing regimens at weeks 48 and 96 (RR, 1.02; 95CI, 1.00-1.03; p0.05). Compared with those receiving the TDF-containing regimens, virologically suppressed HIV-infected patients on the TAF-containing regimens had significant increases in CD4 cell counts (SMD, 0.12; 95CI, 0.08 to 0.17; p<0.05), renal and bone parameters at the hip (RR, 2.86; 95CI, 2.24-3.64; p<0.05) and the spine (RR, 2.43; 95 CI, 2.03-2.90; p<0.05) between weeks 48 and 96. Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens, resulting in better viral suppression, better immune reconstruction, and less bone and renal problems.

5 September 2016 in Tropical Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
XTXing-Bao Tao
Xing-Bao Tao
WPWei Peng
Wei Peng
XYXiao-Qin Yu
Xiao-Qin Yu
DXDa-Shuai Xie
Da-Shuai Xie
MHMeibian Hu
Meibian Hu
CWChun Wu
Chun Wu
Determination of heavy metals in chinese prickly ash from different production areas using inductively coupled plasma-mass spectrometry